{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.044","value":"74.83"},{"groupId":"OG001","spread":"1.044","value":"75.61"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"292"},{"groupId":"OG001","value":"288"}],"units":"Participants"}],"title":"Cycle 1 (Baseline)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.289","value":"69.71"},{"groupId":"OG001","spread":"1.097","value":"75.49"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"260"},{"groupId":"OG001","value":"274"}],"units":"Participants"}],"title":"Cycle 2"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.278","value":"69.67"},{"groupId":"OG001","spread":"1.142","value":"74.09"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"241"},{"groupId":"OG001","value":"265"}],"units":"Participants"}],"title":"Cycle 3"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.307","value":"66.52"},{"groupId":"OG001","spread":"1.109","value":"74.93"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"227"},{"groupId":"OG001","value":"249"}],"units":"Participants"}],"title":"Cycle 4"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.340","value":"68.34"},{"groupId":"OG001","spread":"1.179","value":"74.61"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"219"},{"groupId":"OG001","value":"234"}],"units":"Participants"}],"title":"Cycle 5"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.396","value":"66.27"},{"groupId":"OG001","spread":"1.172","value":"75.69"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"210"},{"groupId":"OG001","value":"231"}],"units":"Participants"}],"title":"Cycle 6"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.447","value":"67.42"},{"groupId":"OG001","spread":"1.222","value":"73.98"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"200"},{"groupId":"OG001","value":"220"}],"units":"Participants"}],"title":"Cycle 7"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.376","value":"68.33"},{"groupId":"OG001","spread":"1.260","value":"74.49"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"185"},{"groupId":"OG001","value":"212"}],"units":"Participants"}],"title":"Cycle 8"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.556","value":"68.31"},{"groupId":"OG001","spread":"1.338","value":"74.06"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"177"},{"groupId":"OG001","value":"203"}],"units":"Participants"}],"title":"Cycle 9"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.367","value":"64.43"},{"groupId":"OG001","spread":"1.264","value":"73.37"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"250"},{"groupId":"OG001","value":"250"}],"units":"Participants"}],"title":"End of treatment (EOT)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"309"},{"groupId":"OG001","value":"306"}],"units":"Participants"}],"description":"Patient-reported outcomes (PROs) assessed health-related quality of life (QoL) by using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30), which was a 30-item questionnaire with global QoL scale, 5 multi-item functional scales (physical, role, emotional, cognitive, \\& social functioning), 3 multi-item symptom scales (fatigue, nausea/vomiting, \\& pain), and 6 single item symptom scales for other cancer-related symptoms (dyspnea, sleep disturbance, appetite loss, constipation, diarrhea, \\& the financial impact of cancer). The questionnaire includes 28 items with 4-point Likert type responses from \"not at all\" to \"very much\" to assess functioning \\& symptoms; 2 items with 7-point Likert scales for global health \\& overall QoL. All responses were converted to a 0 to 100 scale using a standard scoring algorithm, higher scores represented better level for functioning/QoL \\& more severe for symptoms.","dispersionType":"Standard Error","groups":[{"description":"Participants received Sunitinib on 9 6-week cycles on 4/2 dosing schedule: 4 weeks on, 2 weeks off.","id":"OG000","title":"Sunitinib"},{"description":"Participants received Placebo on 9 6-week cycles with 4/2 dosing schedule: 4 weeks on, 2 weeks off.","id":"OG001","title":"Placebo"}],"paramType":"MEAN","populationDescription":"ITT population included all participants who were randomized, with study drug assignment designated according to initial randomization, regardless of whether participants received study drug or a different drug from that to which they were randomized. Here, 'Number analyzed' signifies the number of participants evaluable at specified time-points.","reportingStatus":"POSTED","timeFrame":"Cycle 1(Day 1); subsequent cycles (Day 1) and end of treatment/withdrawal (ie, up to 1 year)","title":"Patient-Reported Outcomes (PROs)- European Organization for Research and Treatment of Cancer (EORTC) QLQ C30: Observed Means in Global Health Status / Quality of Life Scale Scores","type":"SECONDARY","unitOfMeasure":"Scores on scale"}